Anavex Life Sciences (AVXL) to Release Earnings on Wednesday

Anavex Life Sciences (NASDAQ:AVXL) is anticipated to issue its Q1 2026 results before the market opens on Wednesday, February 11th. Analysts expect Anavex Life Sciences to post earnings of ($0.10) per share for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, February 9, 2026 at 8:30 AM ET.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings results on Tuesday, November 25th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. During the same period in the prior year, the business earned ($0.14) EPS. On average, analysts expect Anavex Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Anavex Life Sciences Price Performance

Shares of NASDAQ:AVXL opened at $4.39 on Wednesday. Anavex Life Sciences has a 1 year low of $2.86 and a 1 year high of $13.99. The company has a market capitalization of $392.25 million, a PE ratio of -8.13 and a beta of 1.21. The business has a fifty day moving average price of $4.27 and a two-hundred day moving average price of $7.25.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. D. Boral Capital restated a “buy” rating and set a $24.00 price objective on shares of Anavex Life Sciences in a report on Tuesday, January 6th. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Anavex Life Sciences in a research report on Friday, December 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Anavex Life Sciences in a research note on Monday, December 29th. Finally, Jones Trading downgraded Anavex Life Sciences from a “buy” rating to a “hold” rating in a research note on Friday, October 24th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $22.00.

Hedge Funds Weigh In On Anavex Life Sciences

A number of large investors have recently made changes to their positions in the stock. State of Wyoming bought a new stake in shares of Anavex Life Sciences during the 2nd quarter valued at $26,000. Quarry LP bought a new position in Anavex Life Sciences in the 3rd quarter worth about $36,000. Russell Investments Group Ltd. grew its holdings in Anavex Life Sciences by 11,540.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,984 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 6,924 shares in the last quarter. Prudential Financial Inc. bought a new stake in shares of Anavex Life Sciences during the second quarter valued at about $95,000. Finally, Sei Investments Co. purchased a new stake in shares of Anavex Life Sciences in the second quarter worth about $107,000. 31.55% of the stock is owned by institutional investors.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.